| |
AbCellera unlocks high-value drug classes, targets, and modalities, including T–cell engagers, antibody-drug conjugates, transmembrane proteins, and peptide-MHCs. Explore More.
|
|
Today’s Big NewsFeb 1, 2024 |
| By Annalee Armstrong Think Roche is out of the Alzheimer’s disease business? Think again. |
|
|
|
By Nick Paul Taylor Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” |
By Max Bayer Merck plans to launch more phase 3 trials in 2024 than it did in 2023, underscoring the company's mid-to-late-stage growth plan. Meanwhile, CEO Rob Davis says the company is hunting for more mid-sized deals. |
By Gabrielle Masson Former Eisai leader Ivan Cheung, the face of approved Alzheimer's disease medicine Leqembi, is taking the top spot at NextPoint Therapeutics. |
By Nick Paul Taylor Kyverna Therapeutics has laid the foundations for the next major IPO of 2024. Having filed last month, the autoimmune cell therapy biotech set the terms for an offering that could gross around $180 million Thursday. |
By Gabrielle Masson Takeda is paying Protagonist Therapeutics $300 million upfront to develop and commercialize a late-stage rare hematology asset, inking a pact that gives the California-based biotech the chance to write its own ending. |
By Max Bayer Novavax says 12% of its workforce was cut as part of a second wave of layoffs announced at the end of 2023, bringing last year’s full-year staff reduction to about 30%. |
By Helen Floersh A case series published Jan. 29 in Nature Medicine by scientists at University College London reported that five patients who were given growth hormones derived from human cadavers as part of an obsolete childhood medical treatment later developed early-onset Alzheimer’s disease. |
By Joseph Keenan Recruitment specialist Trialbee and Massive Bio, which uses an AI-enabled mapping platform to track patient experiences, are partnering to boost enrollment of cancer patients into ongoing clinical trials. |
By Eric Sagonowsky Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs. |
By Joseph Keenan Ichor Life Sciences, a CRO based in upstate New York, has launched a clinical trial services unit to serve clients in preclinical studies through late-stage trials and regulatory approval. |
Fierce podcastsDon’t miss an episode |
| | While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
